Raymond James Financial Inc. acquired a new position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 371,996 shares of the company's stock, valued at approximately $2,946,000. Raymond James Financial Inc. owned approximately 0.12% of Amneal Pharmaceuticals as of its most recent SEC filing.
Other large investors have also added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Amneal Pharmaceuticals during the 4th quarter worth about $81,000. Straightline Group LLC bought a new stake in shares of Amneal Pharmaceuticals during the 4th quarter worth approximately $92,000. Cibc World Markets Corp acquired a new stake in shares of Amneal Pharmaceuticals in the 4th quarter valued at approximately $118,000. Janney Montgomery Scott LLC bought a new position in shares of Amneal Pharmaceuticals in the fourth quarter valued at $121,000. Finally, Fox Run Management L.L.C. increased its holdings in Amneal Pharmaceuticals by 69.0% during the fourth quarter. Fox Run Management L.L.C. now owns 20,435 shares of the company's stock worth $162,000 after buying an additional 8,342 shares during the last quarter. Institutional investors and hedge funds own 31.82% of the company's stock.
Wall Street Analyst Weigh In
A number of brokerages have recently commented on AMRX. Barclays lifted their price objective on shares of Amneal Pharmaceuticals from $10.00 to $11.00 and gave the company an "overweight" rating in a research report on Monday, March 3rd. JPMorgan Chase & Co. raised Amneal Pharmaceuticals from a "neutral" rating to an "overweight" rating and boosted their price target for the stock from $9.00 to $12.00 in a research report on Monday, February 24th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $10.80.
Check Out Our Latest Report on AMRX
Amneal Pharmaceuticals Trading Up 3.0 %
Shares of NASDAQ:AMRX traded up $0.23 on Friday, hitting $7.97. The company had a trading volume of 4,829,305 shares, compared to its average volume of 1,414,630. The stock has a market cap of $2.47 billion, a price-to-earnings ratio of -11.72 and a beta of 1.17. The stock has a 50 day moving average price of $8.02 and a 200 day moving average price of $8.16. Amneal Pharmaceuticals, Inc. has a 1-year low of $6.29 and a 1-year high of $9.48.
Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last announced its quarterly earnings results on Friday, May 2nd. The company reported $0.19 EPS for the quarter, beating analysts' consensus estimates of $0.14 by $0.05. The business had revenue of $695.42 million for the quarter, compared to analyst estimates of $714.78 million. Amneal Pharmaceuticals had a negative net margin of 6.88% and a negative return on equity of 346.26%. Sell-side analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current fiscal year.
Insider Buying and Selling
In other Amneal Pharmaceuticals news, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of Amneal Pharmaceuticals stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $8.35, for a total value of $41,750,000.00. Following the completion of the sale, the insider now owns 48,578,209 shares in the company, valued at $405,628,045.15. The trade was a 9.33 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Gautam Patel sold 80,000 shares of the business's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $8.90, for a total transaction of $712,000.00. Following the completion of the sale, the director now directly owns 1,808,886 shares of the company's stock, valued at $16,099,085.40. This represents a 4.24 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 5,160,000 shares of company stock valued at $43,113,200. Insiders own 26.56% of the company's stock.
About Amneal Pharmaceuticals
(
Free Report)
Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.
Featured Stories
Before you consider Amneal Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amneal Pharmaceuticals wasn't on the list.
While Amneal Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
